Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Synonyms: Pralmorelin
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: GH-releasing peptide
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
Ghrelin-receptor-mediated GH secretion.
Evidence and critical reading
Reported scientific and empirical uses
GH/IGF hormonal axis
Cited for GH elevation, recovery and GHRH combinations.
Human evidence
Human exposure exists; the reviewed FDA safety source does not establish anti-aging efficacy.
Preclinical evidence
Endocrine biomarker effects are not evidence of durable functional benefit.
Critical reading and limitations
Physiology studies measure hormone secretion, not sports benefits or safety of community cycles.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
FDA describes immunogenicity concerns and serious reported events including increased insulin needs, infection and pancreatitis; causality not established.
FDA reports serious-event signals without established causality; distinguish reports from demonstrated effects.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID23485864 · Physiology experiment
Healthy older men/hormonal manipulation.
Physiological IV infusions.
GH response depended on sex hormones/adiposity.
Trial product/population; does not authenticate supplier material or permit simple indirect comparisons.
n = 26
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
GHRP-2 · 0 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry querySource issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID23485864
Differential pulsatile secretagogue control of GH secretion in healthy men.
Norman C, Miles J, Bowers CY, Veldhuis JD.
October 16, 2026
- R06
- SEARCH-PUBMED-ghrp-2
PubMed/MED targeted search: TITLE_ABS:"GHRP-2" AND TITLE_ABS:healthy AND TITLE_ABS:men
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026